The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
Open accessAbstract
BACKGROUND: Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation. OBJECTIVES: This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure. METHODS: ATTR-CM, New York Heart Association functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days. Safety and tolerability were assessed by clinical and laboratory criteria. AG10 plasma levels were measured. TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot). RESULTS: vs. placebo). Average serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, respectively (both p < 0.0001 vs. placebo). Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects. AG10 treatment restored serum TTR to the normal range in all subjects. CONCLUSIONS: AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM. A phase 3 trial is ongoing. (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationYang, B.-J., Han, X.-X., Yin, L.-L., Xing, M.-Q., Xu, Z.-H., & Xue, H.-W. (2016) · Nature Communications · doi:10.1038/ncomms11388 · Cited by 1,202
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Diagnosis and Management of the Cardiac Amyloidoses
Falk, R. H. (2005) · Circulation · doi:10.1161/circulationaha.104.489187 · Cited by 791
Self-citationTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Bulawa, C. E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121005109 · Cited by 742
Transthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
Sperry, B. W., Reyes, B. A., Ikram, A., Donnelly, J. P., Phelan, D., Jaber, W. A., Shapiro, D., Evans, P. J., Maschke, S., Kilpatrick, S. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.092 · Cited by 358
Self-citationCoelho, T., Maurer, M. S., & Suhr, O. B. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 339
Self-citationTrans -Suppression of Misfolding in an Amyloid Disease
Hammarström, P., Schneider, F., & Kelly, J. W. (2001) · Science · doi:10.1126/science.1062245 · Cited by 293
The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans
Quarta, C. C., Buxbaum, J. N., Shah, A. M., Falk, R. H., Claggett, B., Kitzman, D. W., Mosley, T. H., Butler, K. R., Boerwinkle, E., & Solomon, S. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404852 · Cited by 263
Self-citationRuberg, F. L., Maurer, M. S., Judge, D. P., Zeldenrust, S., Skinner, M., Kim, A. Y., Falk, R. H., Cheung, K. N., Patel, A. R., Pano, A., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.04.015 · Cited by 261
Self-citationParman, Y., Adams, D., Obici, L., Galán, L., Guergueltcheva, V., Suhr, O. B., & Coelho, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000288 · Cited by 238
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300761110 · Cited by 198
Self-citationAssociation Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis
Geller, H. I., Singh, A., Alexander, K. M., Mirto, T. M., & Falk, R. H. (2017) · JAMA · doi:10.1001/jama.2017.9236 · Cited by 190
Self-citationSant'Anna, R., Gallego, P., Robinson, L. Z., Pereira-Henriques, A., Ferreira, N., Pinheiro, F., Esperante, S., Pallares, I., Huertas, O., Rosário Almeida, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10787 · Cited by 177
Tojo, K., Sekijima, Y., Kelly, J. W., & Ikeda, S. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.08.014 · Cited by 153
Miller, M., Pal, A., Albusairi, W., Joo, H., Pappas, B., Tuhin, M. T. H., Liang, D., Jampala, R., Liu, F., Khan, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00817 · Cited by 123
Self-citationQuarta, C. C., Kruger, J. L., & Falk, R. H. (2012) · Circulation · doi:10.1161/circulationaha.111.069195 · Cited by 123
Self-citationHanson, J. L. S., Arvanitis, M., Koch, C. M., Berk, J. L., Ruberg, F. L., Prokaeva, T. B., & Connors, L. H. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004000 · Cited by 110
Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution
SEBASTIÃO, M. P., Lamzin, V. S., Saraiva, M. J., & Damas, A. M. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4415 · Cited by 96
Fox, J. C., Hellawell, J. L., Rao, S., O’Reilly, T. E., Lumpkin, R., Jernelius, J. A., Gretler, D. D., & Sinha, U. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.700 · Cited by 68
Self-citationGenetic Stabilization of Transthyretin, Cerebrovascular Disease, and Life Expectancy
Hornstrup, L. S., Frikke‐Schmidt, R., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301273 · Cited by 64
Coelho, T., Chorão, R., Sousa, A., Alves, I. L., Torres, M. F., & Saraiva, M. J. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(96)88826-2 · Cited by 61
Choi, S., & Kelly, J. W. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.050 · Cited by 51
Structure of Monomeric Transthyretin Carrying the Clinically Important T119M Mutation
Kim, J. H., Oroz, J., & Zweckstetter, M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608516 · Cited by 22
Cited by
Transthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Self-citationKittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
Self-citationSeferovic, P. M., Ponikowski, P., Anker, S. D., Bauersachs, J., Chioncel, O., Cleland, J. G. F., de Boer, R. A., Drexel, H., Ben Gal, T., Hill, L., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1531 · Cited by 611
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Gillmore, J. D., Judge, D. P., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S., Grogan, M., Hanna, M., Hoffman, J., Masri, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305434 · Cited by 546
Self-citationPrevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis
Nitsche, C., Scully, P. R., Patel, K. P., Kammerlander, A. A., Koschutnik, M., Dona, C., Wollenweber, T., Ahmed, N., Thornton, G. D., Kelion, A. D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.006 · Cited by 377
Metadata
- Authors
- Judge, D. P., Heitner, S. B., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., Selby, V. N., Jacoby, D., Hanna, M., Nativi-Nicolau, J., Patel, J., Rao, S., Sinha, U., Turtle, C. W., & Fox, J. C.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 74
- Issue
- 3
- Pages
- 285-295
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2921829640
- Cited by
- 263
- References
- 31
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.